Know Cancer

or
forgot password

A Phase I Study to Characterize the Pharmacokinetics of Topotecan at 4 mg/m2 Administered Weekly as a 30-Minute Intravenous Infusion in Patients With Cancer


Phase 1
18 Years
N/A
Not Enrolling
Both
Malignancy, Solid Tumor Cancer, Cancer

Thank you

Trial Information

A Phase I Study to Characterize the Pharmacokinetics of Topotecan at 4 mg/m2 Administered Weekly as a 30-Minute Intravenous Infusion in Patients With Cancer

Inclusion Criteria


Inclusion criteria:

- Written informed consent

- Performance status of 0, 1, or 2 on the Eastern Co-operative Oncology Group (ECOG)
Scale

- Predicted life expectancy of at least 3 months

- Subjects with histologically or cytologically confirmed advanced solid tumors who
have failed conventional therapy for their tumor type or have a tumor type for which
no standard effective therapy exists; OR Patients for whom single-agent topotecan
therapy is suitable

- At least 4 weeks since last chemotherapy, radiotherapy, biologic therapy or surgery

- Must be free of post-treatment side effects (with the exception of alopecia)

- No concurrent chemotherapy, biologic therapy or radiotherapy is allowed

- Hemoglobin = 9.0 g/dL

- WBC = 3,500/mm3 [= 3.5 x 109/L]

- Neutrophils = 1,500/mm3 [= 1.5 x 109/L]

- Platelets = 100,000/mm3 [= 100.0 x 109/L]

- Calculated creatinine clearance=60 mL/min using the Cockcroft-Gault formula

- Serum bilirubin < 2.0 mg/dL (34 ┬Ámol/L) AST, SGPT/ALT and alkaline phosphatase < 2
times the upper limit of normal if liver metastases cannot be visualized by abdominal
computed tomography (CT) or magnetic resonance imaging (MRI scan)

- If liver metastases are present, subjects with < 5 times the upper limit of normal
are eligible to participate

Exclusion criteria:

- Women who are pregnant or lactating

- Women subjects of childbearing potential who refuse to abstain from sexual
intercourse or practice adequate contraception. Childbearing potential is defined as
women who are not surgically sterilized (i.e. have not had a hysterectomy, bilateral
oophorectomy [ovariectomy], or bilateral tubal ligation) or post-menopausal (i.e.,
documented absence of menses for one year prior to entry into the study).

- Men unwilling to abstain from sex or use effective contraception during the study and
for 3 months following completion of topotecan treatment

- Subjects with uncontrolled emesis, regardless of etiology

- Active infection

- Concurrent severe medical problems unrelated to the malignancy, which would
significantly limit full compliance with the study or expose the patient to extreme
risk

- Treatment with another investigational drug within 30 days or five half-lives prior
to entry into the study (whichever is longer)

- History of allergic reactions to compounds chemically related to topotecan.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

CL and Vss of total topotecan

Principal Investigator

GSK Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:

GlaxoSmithKline

Authority:

United States: Food and Drug Administration

Study ID:

HYT104152

NCT ID:

NCT00361803

Start Date:

September 2006

Completion Date:

Related Keywords:

  • Malignancy
  • Solid Tumor Cancer
  • Cancer
  • chemotherapy
  • recurrent
  • refractory
  • research
  • cancer
  • pharmacokinetics
  • Neoplasms

Name

Location

GSK Investigational Site Phoenix, Arizona  85013 - 4496